SCHEMBL216615

SCHEMBL216615

Nc1nc2cc(Cl)ccc2[nH]1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3E A5X5Y0 1/20 0.72
HTR3B O95264 1/20 0.72
HTR3A P46098 1/20 0.72
BACE1 P56817 1/20 0.72
HTR3D Q70Z44 1/20 0.72
HTR3C Q8WXA8 1/20 0.72
ALDH1A1 P00352 3/20 0.53
MASP2 O00187 1/20 0.53
MEN1 O00255 1/20 0.53
NUDT1 P36639 1/20 0.53
KMT2A Q03164 1/20 0.53
AOC3 Q16853 1/20 0.53
FABP6 P51161 1/20 0.50
TYMS P04818 4/20 0.49
PIK3CG P48736 1/20 0.48
PLAU P00749 1/20 0.47
F7 P08709 2/20 0.44
F3 P13726 2/20 0.44
NR4A2 P43354 2/20 0.44
LTA4H P09960 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL215261 0.98 HTR3E (0.70) HTR3EHTR3BHTR3ABACE1HTR3D
SCHEMBL5679783 0.85 BACE1 (0.59) HTR3EHTR3BHTR3ABACE1HTR3D
SCHEMBL658809 0.84 HTR3E (1.00) HTR3EHTR3BHTR3ABACE1HTR3D
SCHEMBL117352 0.81 BACE1 (0.54) HTR3EHTR3BHTR3ABACE1HTR3D
Bromide SCHEMBL2381776 0.80 BACE1 (0.53) HTR3EHTR3BHTR3ABACE1HTR3D
SCHEMBL14920005 0.80 HTR3E (0.53) HTR3EHTR3BHTR3ABACE1HTR3D
SCHEMBL118057 0.79 MEN1 (0.57) HTR3EHTR3BHTR3ABACE1HTR3D
SCHEMBL29449363 0.79 MEN1 (0.57) HTR3EHTR3BHTR3ABACE1HTR3D
SCHEMBL1171146 0.79 ALDH1A1 (0.53) HTR3EHTR3BHTR3ABACE1HTR3D
SCHEMBL1192946 0.79 F7 (0.47) HTR3EHTR3BHTR3ABACE1HTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10292390-B2 Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2019-05-21 US claimed
CN-105384693-B Compound, its synthetic method and the purposes of the structure of bisazo containing benzoxazole ring 盐城工学院 2018-11-09 CN claimed
CN-105384693-A Compound containing benzoxazole ring bis(azo) structure, synthetic method for compound and use of compound YANCHENG INST TECHNOLOGY 2016-03-09 CN claimed
US-20130136782-A1 Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives WISCONSIN ALUMNI RESEARCH FOUNDATION 2013-05-30 US claimed
EP-2398771-A2 HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2011-12-28 EP claimed
WO-2010096371-A2 HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-26 WO claimed
US-4496727-A ORGANIC PIGMENTS; PLASTICS; LACQUERS; INKS; COATINGS; COLOR FASTNESS CIBA-GEIGY CORPORATION (US) 1985-01-29 US claimed
US-4385174-A FOR PIGMENTS CIBA-GEIGY CORPORATION (US) 1983-05-24 US claimed
US-4349671-A Process for the production of metal complexes of isoindoline azines CIBA-GEIGY CORPORATION (US) 1982-09-14 US claimed
CN-121450114-A Perovskite precursor material for photoelectric conversion and preparation method thereof 广西东岚新型材料有限公司 2026-02-03 CN disclosed
US-20210128561-A1 MRGX Receptor Antagonists KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2021-05-06 US disclosed
US-20210128561-A1 MRGX Receptor Antagonists KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2021-05-06 US disclosed
WO-2021022061-A1 ARYL HYDROCARBON RECEPTOR ACTIVATORS OREGON STATE UNIVERSITY (US) 2021-02-04 WO disclosed
US-10292390-B2 Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2019-05-21 US disclosed
US-4059584-A ANTIINFLAMMATORY PFIZER (US) 1977-11-22 US disclosed
US-4022770-A COLORING CIBA-GEIGY CORPORATION (US) 1977-05-10 US disclosed
US-4011236-A N-(BENZIMIDAZOL-2-YL)ARYLCARBOXAMIDES AS ULTRAVIOLET (UV) LIGHT ABSORBERS MERCK & CO., INC. (US) 1977-03-08 US disclosed
US-4006127-A Cationic diazacyanine dyestuffs BAYER AKTIENGESELLSCHAFT (DT) 1977-02-01 US disclosed
US-4002623-A Anti-inflammatory 1-[3-(dialkylamino)propyl]-2-acylaminobenzimidazoles and 2-acylamino-3-[3-(dialkylamino)-propyl]imidazo[4,5-b]pyridines PFIZER INC. (US) 1977-01-11 US disclosed
US-4000275-A BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES ELI LILLY AND COMPANY (US) 1976-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130136782-A1 Inhibition and Dispersion of Bacterial Biofilms with 2-Aminobenzimidazole Derivatives FLNB, BRI3BP, CCNI HTR3E 1093/4885HTR3B 930/4885HTR3A 1370/4885
US-10292390-B2 Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives FLNB, BRI3BP, CCNI HTR3E 1093/4885HTR3B 930/4885HTR3A 1370/4885
US-20210128561-A1 MRGX Receptor Antagonists MRGPRX2, MRGPRX1, MRGPRX4 HTR3E 246/4885HTR3B 411/4885HTR3A 364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.